Literature DB >> 12654798

Repeat sequences in block 2 of Plasmodium falciparum merozoite surface protein 1 are targets of antibodies associated with protection from malaria.

Spencer D Polley1, Kevin K A Tetteh, David R Cavanagh, Richard J Pearce, Jennifer M Lloyd, Kalifa A Bojang, Daniel M N Okenu, Brian M Greenwood, Jana S McBride, David J Conway.   

Abstract

Human antibodies to the block 2 region of Plasmodium falciparum merozoite surface protein 1 (MSP1) are associated with a reduced prospective risk of clinical malaria. Block 2 is highly polymorphic, but all known alleles can be grouped into three major types. Two of these types (the K1-like and MAD20-like types) contain type-specific sequences (found in all alleles of a particular type) that flank polymorphic tripeptide repeats. These repeats contain both type-specific and subtype-specific sequences. To evaluate the antibody recognition of these parts of block 2, a new panel of six recombinant proteins was used (fused type-specific flanking sequences and two representative repeat sequences for each of the K1-like and MAD20-like types separately). Extensive testing of these antigens and full-length block 2 antigens showed that human serum immunoglobulin G antibodies induced by infection can recognize (i) type-specific epitopes in the repeats, (ii) subtype-specific epitopes in the repeats, or (iii) type-specific epitopes in flanking sequences. A large prospective study in The Gambia showed that antibodies to the repeats are strongly associated with protection from clinical malaria. The results are important for design of a vaccine to induce protective antibodies, and they address hypotheses about repeat sequences in malaria antigens.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12654798      PMCID: PMC152097          DOI: 10.1128/IAI.71.4.1833-1842.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

1.  Allelic dimorphism in a surface antigen gene of the malaria parasite Plasmodium falciparum.

Authors:  K Tanabe; M Mackay; M Goman; J G Scaife
Journal:  J Mol Biol       Date:  1987-05-20       Impact factor: 5.469

2.  Multiple cross-reactivities amongst antigens of Plasmodium falciparum impair the development of protective immunity against malaria.

Authors:  R F Anders
Journal:  Parasite Immunol       Date:  1986-11       Impact factor: 2.280

3.  Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.

Authors:  K A Bojang; P J Milligan; M Pinder; L Vigneron; A Alloueche; K E Kester; W R Ballou; D J Conway; W H Reece; P Gothard; L Yamuah; M Delchambre; G Voss; B M Greenwood; A Hill; K P McAdam; N Tornieporth; J D Cohen; T Doherty
Journal:  Lancet       Date:  2001-12-08       Impact factor: 79.321

4.  Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1).

Authors:  L H Miller; T Roberts; M Shahabuddin; T F McCutchan
Journal:  Mol Biochem Parasitol       Date:  1993-05       Impact factor: 1.759

5.  Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.

Authors:  D B Smith; K S Johnson
Journal:  Gene       Date:  1988-07-15       Impact factor: 3.688

6.  Biased amino acid composition in repeat regions of Plasmodium antigens.

Authors:  F Verra; A L Hughes
Journal:  Mol Biol Evol       Date:  1999-05       Impact factor: 16.240

7.  Fixed, epitope-specific, cytophilic antibody response to the polymorphic block 2 domain of the Plasmodium falciparum merozoite surface antigen MSP-1 in humans living in a malaria-endemic area.

Authors:  H Jouin; C Rogier; J F Trape; O Mercereau-Puijalon
Journal:  Eur J Immunol       Date:  2001-02       Impact factor: 5.532

8.  Characterization of conserved T- and B-cell epitopes in Plasmodium falciparum major merozoite surface protein 1.

Authors:  M Parra; G Hui; A H Johnson; J A Berzofsky; T Roberts; I A Quakyi; D W Taylor
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

9.  Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages.

Authors:  H Bouharoun-Tayoun; C Oeuvray; F Lunel; P Druilhe
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

10.  Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein.

Authors:  M J Blackman; T J Scott-Finnigan; S Shai; A A Holder
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

View more
  39 in total

1.  Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development.

Authors:  Michelle J Boyle; Danny W Wilson; Jack S Richards; David T Riglar; Kevin K A Tetteh; David J Conway; Stuart A Ralph; Jake Baum; James G Beeson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-26       Impact factor: 11.205

2.  Extensive antigenic polymorphism within the repeat sequence of the Plasmodium falciparum merozoite surface protein 1 block 2 is incorporated in a minimal polyvalent immunogen.

Authors:  Kevin K A Tetteh; David R Cavanagh; Patrick Corran; Rosemary Musonda; Jana S McBride; David J Conway
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 3.  Antigenic diversity and immune evasion by malaria parasites.

Authors:  Marcelo U Ferreira; Mônica da Silva Nunes; Gerhard Wunderlich
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

4.  Factors associated with immunoglobulin G subclass polarization in naturally acquired antibodies to Plasmodium falciparum merozoite surface proteins: a cross-sectional survey in Brazilian Amazonia.

Authors:  Kézia K G Scopel; Cor J F Fontes; Marcelo U Ferreira; Erika M Braga
Journal:  Clin Vaccine Immunol       Date:  2006-07

5.  A reduced risk of infection with Plasmodium vivax and clinical protection against malaria are associated with antibodies against the N terminus but not the C terminus of merozoite surface protein 1.

Authors:  Paulo Afonso Nogueira; Fabiana Piovesan Alves; Carmen Fernandez-Becerra; Oliver Pein; Neida Rodrigues Santos; Luiz Hildebrando Pereira da Silva; Erney Plessman Camargo; Hernando A del Portillo
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

6.  Genetic diversity in the Block 2 region of the merozoite surface protein 1 (MSP-1) of Plasmodium falciparum: additional complexity and selection and convergence in fragment size polymorphism.

Authors:  S L Takala; A A Escalante; O H Branch; S Kariuki; S Biswas; S C Chaiyaroj; A A Lal
Journal:  Infect Genet Evol       Date:  2006-03-06       Impact factor: 3.342

7.  Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria.

Authors:  Faith H A Osier; Gregory Fegan; Spencer D Polley; Linda Murungi; Federica Verra; Kevin K A Tetteh; Brett Lowe; Tabitha Mwangi; Peter C Bull; Alan W Thomas; David R Cavanagh; Jana S McBride; David E Lanar; Margaret J Mackinnon; David J Conway; Kevin Marsh
Journal:  Infect Immun       Date:  2008-03-03       Impact factor: 3.441

8.  Target antigen, age, and duration of antigen exposure independently regulate immunoglobulin G subclass switching in malaria.

Authors:  J Eric Tongren; Christopher J Drakeley; Suzanna L R McDonald; Hugh G Reyburn; Alphaxard Manjurano; Watoky M M Nkya; Martha M Lemnge; Channe D Gowda; Jim E Todd; Patrick H Corran; Eleanor M Riley
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

Review 9.  The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis.

Authors:  Freya J I Fowkes; Jack S Richards; Julie A Simpson; James G Beeson
Journal:  PLoS Med       Date:  2010-01-19       Impact factor: 11.069

10.  Population diversity and antibody selective pressure to Plasmodium falciparum MSP1 block2 locus in an African malaria-endemic setting.

Authors:  Nitchakarn Noranate; Franck Prugnolle; Hélène Jouin; Adama Tall; Laurence Marrama; Cheikh Sokhna; Marie-Thérèse Ekala; Micheline Guillotte; Emmanuel Bischoff; Christiane Bouchier; Jintana Patarapotikul; Jun Ohashi; Jean-François Trape; Christophe Rogier; Odile Mercereau-Puijalon
Journal:  BMC Microbiol       Date:  2009-10-15       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.